Thyroid C-Cell Tumors: In rats, Zepbound caused a dose-dependent and treatment-duration-dependent increase in thyroid C-cell tumors
Product Overview: Tirzepatide is a novel once-weekly injectable peptide medication that acts as a dual GIP (glucose-dependent insulinotropic polypeptide) receptor agonist and GLP-1 (glucagon-like peptide-1) receptor agonist
By slowing down the movement of food through the stomach, it helps control blood sugar and support weight loss, but it can also disrupt the normal digestive process
Many supplement brands still use artificial colourants, bulking agents, and unnecessary additives to make products more appealing or easier to produce
Overall, GLP-1 receptor agonist use was associated with a 16% lower risk of developing epilepsy
Clinical studies suggest that patients using semaglutide (Ozempic) lost 5-15% of their body weight, compared to 39% with Trulicity